Early Case Report Documents Kratom Use for Opioid Withdrawal Self-Treatment

Why it matters

Published in 2008, this early NIH-funded case report was among the first to document kratom's use as a self-managed opioid withdrawal remedy in the US, and first to confirm mitragynine's opioid receptor binding.

The big picture

This foundational case laid groundwork for decades of kratom research by demonstrating that patients were already using kratom to manage opioid withdrawal without medical supervision — a pattern that has only accelerated.

Key findings

• • A 43-year-old male used kratom tea to self-manage opioid withdrawal after abruptly stopping hydromorphone injection abuse
• • He spent $15,000/year on kratom and reported substantial pain relief and improved alertness without typical opioid drowsiness
• • Co-administration with modafinil triggered a generalized tonic-clonic seizure; no adulterants were found
• • High-throughput molecular screening confirmed mitragynine binds mu, delta, and kappa opioid receptors

What they say

Case report from the University of Massachusetts Medical School and McLean Hospital/Harvard Medical School, published in Addiction (2008); NIH-funded.

Bottom line

This seminal 2008 case confirmed kratom's opioid receptor binding, its utility for withdrawal self-treatment, and introduced the first warning about potential drug interaction risks.